14-3-3 Proteins Interact with a Hybrid Prenyl-phosphorylation Motif to Inhibit G Proteins
Overview
Authors
Affiliations
Signaling through G proteins normally involves conformational switching between GTP- and GDP-bound states. Several Rho GTPases are also regulated by RhoGDI binding and sequestering in the cytosol. Rnd proteins are atypical constitutively GTP-bound Rho proteins, whose regulation remains elusive. Here, we report a high-affinity 14-3-3-binding site at the C terminus of Rnd3 consisting of both the Cys241-farnesyl moiety and a Rho-associated coiled coil containing protein kinase (ROCK)-dependent Ser240 phosphorylation site. 14-3-3 binding to Rnd3 also involves phosphorylation of Ser218 by ROCK and/or Ser210 by protein kinase C (PKC). The crystal structure of a phosphorylated, farnesylated Rnd3 peptide with 14-3-3 reveals a hydrophobic groove in 14-3-3 proteins accommodating the farnesyl moiety. Functionally, 14-3-3 inhibits Rnd3-induced cell rounding by translocating it from the plasma membrane to the cytosol. Rnd1, Rnd2, and geranylgeranylated Rap1A interact similarly with 14-3-3. In contrast to the canonical GTP/GDP switch that regulates most Ras superfamily members, our results reveal an unprecedented mechanism for G protein inhibition by 14-3-3 proteins.
New insights into protein-protein interaction modulators in drug discovery and therapeutic advance.
Nada H, Choi Y, Kim S, Jeong K, Meanwell N, Lee K Signal Transduct Target Ther. 2024; 9(1):341.
PMID: 39638817 PMC: 11621763. DOI: 10.1038/s41392-024-02036-3.
The metastasis-promoting P1597L mutation in PlexinB1 enhances Ras activity.
Garg R, Williamson M BMC Cancer. 2024; 24(1):1004.
PMID: 39138404 PMC: 11321201. DOI: 10.1186/s12885-024-12762-0.
Molecular basis and current insights of atypical Rho small GTPase in cancer.
Huang H, Wang S, Guan Y, Ren J, Liu X Mol Biol Rep. 2024; 51(1):141.
PMID: 38236467 DOI: 10.1007/s11033-023-09140-7.
PIM1 controls GBP1 activity to limit self-damage and to guard against pathogen infection.
Fisch D, Pfleiderer M, Anastasakou E, Mackie G, Wendt F, Liu X Science. 2023; 382(6666):eadg2253.
PMID: 37797010 PMC: 7615196. DOI: 10.1126/science.adg2253.
Tawfeeq N, Lazarte J, Jin Y, Gregory M, Lamango N Oncotarget. 2023; 14():243-257.
PMID: 36961909 PMC: 10038354. DOI: 10.18632/oncotarget.28390.